Dapagliflozin-d4

Dapagliflozin-d4 (BMS-512148-d4) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine[1]. Dapagliflozin induces HIF1 expression and attenuates renal IR injury[2].

Product Specifications

CAS Number

[1224234-25-6]

Product Name Alternative

BMS-512148-d4

UNSPSC

12352005

Target

Isotope-Labeled Compounds; SGLT

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cancer

Smiles

O[C@H]1[C@H](C2=CC(CC3=C([2H])C([2H])=C(C([2H])=C3[2H])OCC)=C(C=C2)Cl)O[C@@H]([C@H]([C@@H]1O)O)CO

Molecular Formula

C21H21D4ClO6

Molecular Weight

412.90

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Pelissier T, et al. The orofacial capsaicin test in rats: effects of different capsaicin concentrations and morphine. Pain. 2002 Mar;96 (1-2) :81-7.